Monkez Moteih Yousif

Monkez Moteih Yousif

Auto-generated profile, based on publicly available information

Monkez Moteih Yousif

Internal Medicine Department, Zagazig University, Sharkia, Egypt

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
HOHeba Omar
Heba Omar
WAW. El Akel
W. El Akel
TET. Elbaz
T. Elbaz
MEMohamed El-Kassas
Mohamed El-Kassas
KEK. Elsaeed
K. Elsaeed
YSY. El Shazly
Y. El Shazly

31 January 2019 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
MYMonkez Moteih Yousif
Monkez Moteih Yousif
ASAyman M. E. M. Sadek
Ayman M. E. M. Sadek
HFHesham Ahmad Farrag
Hesham Ahmad Farrag
FSFayrouz Othman Selim
Fayrouz Othman Selim
EHEmad Fawzi Hamed
Emad Fawzi Hamed
RSRasha Ibrahim Salama
Rasha Ibrahim Salama

10 January 2015 in International Journal of TROPICAL DISEASE & Health
Verified
Journal Article
Open access
PDF file
FAFatma A. Amer
Fatma A. Amer
MGMaha Gohar
Maha Gohar
MYMonkez Yousef
Monkez Yousef
Hepatitis C virus constitutes an epidemic in Egypt having the highest prevalence in the world of 14.7%. The reasons behind this unique epidemic may be dated back to iatrogenic role of parenteral antischistosomal therapy campaigns to control endemic schistosomiasis. Other routes of infection are contributing to the ongoing HCV transmission. The prevalent genotype in Egypt is type 4 (73%), the origin, evolution, and dynamics are difficult to determine. Risk factors for acquiring HCV infection include: History of antischistosomal injection treatment before 1986, old age, male gender, and residence in rural areas. Other risk factors include; injection therapy, blood transfusion prior to 1994, exposure to various facility-based medical procedures, and occupational transmission among health care workers. In community settings, a set of risk factors, mostly related to prevailing social and cultural conditions, are responsible for maintaining the high rates of HCV transmission. Chronic HCV is the main cause of liver cirrhosis and liver cancer in Egypt and, indeed, one of the top five leading causes of death. It kills an estimated 40,000 Egyptians a year. When talking about children, current HCV seroprevalenceis high, approximately 5-8%. It is to be emphasized that HCV infection is not always benign in the childhood period in Egypt. It has been shown that blood transfusion, surgical procedures, dental treatment, male circumcision and age above 10 years are important risk factors associated with anti-HCV antibody prevalence. In addition, vertical transmissions, and household transmission have been documented as routes of transmission. Occult HCV infection is defined as elevated liver function tests and negative HCV antibodies in serum, while HCV RNA is detectable in liver tissue and peripheral polymorphonuclear cells (PBMCs). Interest in occult HCV has emerged recently in Egypt. Studies at a national level are being carried out, but no results have yet been released. Many small scale studies have been performed among particular patient groups, which have highlighted the importance of this disease entity.

1 September 2018
Verified
Journal Article
Closed access
MYMonkez Yousif
Monkez Yousif
AFAhmed Elsadek Fakhr
Ahmed Elsadek Fakhr
EMEmad Abdelhamid Morad
Emad Abdelhamid Morad
HKHesham Kelani
Hesham Kelani
EHEmad Hamed
Emad Hamed
HFHesham A Farrag
Hesham A Farrag

1 September 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
FAFatma Amer
Fatma Amer
MYMonkez M Yousif
Monkez M Yousif
NHNoha Mohammed Hammad
Noha Mohammed Hammad
DGDamir Garcia-Cehic
Damir Garcia-Cehic
Josep GregoriJosep Gregori
Josep Gregori
JQJosep Quer
Josep Quer
Purpose: To study resistance-associated substitutions using next-generation sequencing in Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment. Methods: The current study describes three cases of treatment failure in patients referred to Zagazig Viral Hepatitis Treatment Center (ZVHTC), Sharkia Governorate, Egypt. RAS were identified and characterized using deep sequencing. The first patient had breakthrough while receiving a daclatasvir (DCV)+sofosbuvir (SOF) regimen, patient 2 relapsed after treatment with DCV+SOF+ribavirin (RBV), and patient 3 relapsed after DCV+SOF therapy. A serum sample was collected from each patient at failure and sent to Vall d’Hebron Research Institute at Hospital Universitari Vall d’Hebron in Barcelona (Spain) for deep-sequencing study to identify and characterize the RAS present in the samples. Results: The following were identified: L28M, L30S and L28M+L30S in patient 1, L30R in patient 2, and R155C, D168E, L28M, L30H, L30S, L28M+L30H, and L28M+L30S in patient 3. Conclusion: To the best of our knowledge, this is the first report from Egypt of patients failing DAA-based therapy, describing the associated RAS. This information will be of help to understand the natural history of HCV in Egyptian patients and guide the proper choice of retreatment protocols.

21 June 2020 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
MYMonkez M. Yousif
Monkez M. Yousif
HAHussien Ahmed
Hussien Ahmed
HEHany M. Elsadek
Hany M. Elsadek
ASAli M. Shendi
Ali M. Shendi
TGTamer M. Gouda
Tamer M. Gouda
MZMahmoud H. Zahran
Mahmoud H. Zahran